Skip to main content
. 2020 Oct 28;85:153396. doi: 10.1016/j.phymed.2020.153396

Fig. 1.

Fig. 1:

Infection pathway of cellular infectivity of SARS-COV-2 via Host cell protease surface receptor and subsequent drug targeting through phytopharmaceuticals mediated nasal or oral nebuliser for blocking of host-virus interaction during early endocytosis during therapeutic intervention.